Compositions for wound healing containing metal organic framework materials
By using metal organic frame materials and hydrophilic superabsorbent polymers in wound dressings, the problem of insufficient cell migration and safety in the prior art is solved, and high efficiency is achieved. Safe wound healing effect.
Patent Information
- Application Number
- CN202080062508.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-12-10
- Filing Date
- 2020-12-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-12-11
AI Technical Summary
Existing wound healing materials are difficult to effectively promote skin cell migration and accelerate wound healing, and there are challenges in ensuring safety while maintaining a humid environment.
Compositions containing metal organic frame material (MOF) as active ingredient, combined with hydrophilic superabsorbent polymers are used to prepare wound dressings, promote fibroblast migration and accelerate wound healing.
Excellent wound healing effect was achieved, significantly improved wound recovery rate, and there was no significant difference in cytotoxicity with the control group, demonstrating a high safety and time-observable healing process.
Smart Images

Figure CN114364379B_ABST
Abstract
Description
Technical Field
[0001] In the specification, a composition for wound healing including a metal organic framework material (MOF) as an active ingredient, and a wound dressing including a hydrophilic superabsorbent polymer and MOF are disclosed.
[0002] [Korean National R&D Project supporting this invention]
[0003] This research was supported by the Technology Development Project No. [S2737226] from the Ministry of SMEs and Startups of Korea. Background Art
[0004] The skin consists of three main layers: the epidermis, dermis, and subcutaneous fat. Each layer of skin tissue is composed of various cells and surrounding substances responsible for the skin's multiple functions. When the skin is damaged, the damaged area will be invaded by bacteria and foreign toxins, and the skin's defense function against them will cause inflammation.
[0005] Wound healing is the tissue recovery process in response to damaged skin. It is a complex biological process that includes chemotaxis, cell differentiation and replication, lipoprotein synthesis, and angiogenesis.
[0006] In the tissue recovery process of damaged skin, cell proliferation and cell migration work together to repair damaged skin sites. That is, in order to repair damaged skin tissue, a process of activating skin cell generation and migrating newly generated cells to the damaged site and forming new skin tissue is experienced. Therefore, for wound healing, it is necessary to use drugs that are responsible for promoting skin cell proliferation and controlling the migration of generated skin cells to damaged skin sites.
[0007] Meanwhile, in order to accelerate wound healing and minimize various secondary side effects, wound treatment using appropriate covering materials or dressings is essential. As a conventional treatment method for skin wounds such as burns, trauma, wounds, and bedsores, the wound is treated by applying an antiseptic to the wound, covering the wound site with an absorbent material such as gauze or cotton to absorb exudate produced by the wound, and drying the wound site. However, recent studies have shown that maintaining an appropriate moist environment is quite effective for wound treatment, and wound dressings of various types and materials have been developed and marketed.
[0008] Under such background, the present inventors have studied materials that can exhibit excellent wound healing effects and be prepared into wound dressings, thereby completing the present invention.
[0009] Prior art literature
[0010] Patent Literature
[0011] (Patent Document 1) KR 10-2019-0072333A
[0012] (Patent Document 2) KR 10-2019-0083593A
[0013] (Patent Document 3) KR 10-2010-0023073A Summary of the invention
[0014] The present invention relates to a composition for wound healing, which comprises a metal organic framework material (MOF) as an active ingredient.
[0015] The present invention also provides a wound dressing comprising a hydrophilic superabsorbent polymer and MOF.
[0016] Technical Solution
[0017] In one aspect, the present invention provides a composition for wound healing, comprising a metal organic framework material (MOF) as an active ingredient.
[0018] In another aspect, the present invention provides a wound dressing comprising a hydrophilic superabsorbent polymer and a MOF.
[0019] Beneficial Effects
[0020] The present invention relates to a composition comprising a metal organic framework material (MOF), which has excellent wound healing ability, specifically, has an excellent effect of healing wounds by promoting fibroblast migration, has no significant difference in cytotoxicity from a control group, and therefore exhibits excellent safety when applied to a wound site, and has an excellent wound recovery rate that can be visually confirmed over time in the case of a wound dressing comprising a hydrophilic superabsorbent polymer and MOF. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 : is a graph showing the results of cytotoxicity tests on fibroblasts treated with a metal organic framework material (MOF) according to one embodiment of the present invention. The x-axis represents the MOF concentration (control; 0.1, 1 and 10 μg / ml) treated for 24 hours, 48 hours and 72 hours, and the y-axis represents fibroblast viability.
[0022] Figure 2a and 2b The wound healing ability of MOF was shown when mouse fibroblasts with a scratch were treated with MOF according to one embodiment of the present invention, wherein Figure 2a is a set of images showing the wound healing capabilities of fibroblast migration over time, Figure 2b is a graph comparing the migration areas of fibroblasts. Figure 2bIn the figure, the x-axis represents the concentration of MOF treated for 5, 10 and 20 hours (control; 1, 10 and 100 ng / ml), and the y-axis represents the migration area of fibroblasts (%). The larger the migration area of fibroblasts, the better the wound healing ability.
[0023] Figure 3a and 3b A set of images showing the injured back area of rats at 0, 3, 7, 10 and 14 days after dressing with a MOF-dispersed hydrogel (control; content: 0 wt%, 0.2 wt%) according to one embodiment of the present invention ( Figure 3a ), and a graph showing the comparison of wound contracture areas ( Figure 3b ). Figure 3b The x-axis of the curve graph represents the time (days) after dressing, and the y-axis represents the wound contracture area (%). The smaller the wound contracture area, the better the wound healing ability. DETAILED DESCRIPTION
[0024] Hereinafter, the present invention will be described in detail.
[0025] In the present invention, the term "metal-organic framework (MOF)" refers to a porous material in which a metal cluster and an organic linker (or an organic bridging ligand) are connected by a coordination bond to form a three-dimensional structure, and various MOFs can be formed according to the selection of metal ions and organic ligands. MOF is porous, which means that there is an empty space in its structure, and the pore size, porosity, three-dimensional structure and surface area can be designed in various ways according to the type and combination type of the metal ions and organic ligands constituting the MOF. Due to this porosity, MOF has a very large surface area and an open-pore structure, so a large amount of molecules or solvents can be moved compared to other porous materials known in the art, and when used as a catalyst or gas storage body, it has the advantage of maximizing the efficacy due to many active sites. In addition, MOF is not easily deformed at high temperatures and has a rigid skeleton, so it has excellent chemical stability and excellent thermal stability.
[0026] In one aspect, the present invention provides a composition for wound healing, comprising MOF as an active ingredient.
[0027] In one embodiment of the present invention, the MOF may include one or more selected from the group consisting of Al and Zr, and one or more organic ligands selected from the group consisting of: 4,4'-biphenyl dicarboxylic acid, benzene-1,4-dicarboxylic acid, 9,10-anthracene dicarboxylic acid, biphenyl-3,3,5,5'-tetracarboxylic acid, biphenyl-3,4',5-tricarboxylic acid, 5-bromoisophthalic acid, 5-cyano-1,3-benzenedicarboxylic acid, 2,2-diamino-4,4'-stilbene dicarboxylic acid, 2,5-diaminoisophthalic acid, Phthalic acid, 1,1,2,2-tetrakis(4-carboxyphenyl)ethylene, 2,5-dihydroxyterephthalic acid, 2,2-dinitro-4,4-stilbenedicarboxylic acid, 5-ethynyl-1,3-phthalic acid, 2-hydroxyterephthalic acid, 2,6-naphthalenedicarboxylic acid, 1,2,4,5-tetrakis(4-carboxyphenyl)benzene, 4,4,4″-s-triazine-2,4,6-triyl-tribenzoic acid, 1,3,5-tricarboxybenzene, 1,4,7,10-tetraazacyclododecane-N,N',N",N ”'-tetraacetic acid, 1,3,5-tri(4-carboxy[1,1'-biphenyl]-4-yl)benzene, 1,3,5-tri(4-carboxyphenyl)benzene and 1,3,5-tricarboxyphenylethynylbenzene. Specifically, MOF can be Zr6O4(OH)4(BTC)2(HCOO)6(MOF-808), Zr6O4(OH)4(fumaric acid)6(MOF-801), Zr6O6(BDC)6, Zr6O6(NH-2-BDC)6, Zr6 O6(OH)4(BPDC)6, Al3O(OH)(H2O)2(BDC-NH2)3 or Al(OH)(BDC), and more particularly, Zr6O4(OH)4(BTC)2(HCOO)6(MOF-808) can be used to ensure stability when treating injured skin parts and heal wounds. In addition, there is no limitation on the type of MOF as long as it has safety, stability and wound healing ability so that it can be used as an active ingredient of wound dressing.
[0028] In one embodiment of the present invention, MOF can promote skin cell migration. In addition, in one embodiment of the present invention, a composition comprising MOF can promote skin cell migration. In the wound healing process, cell proliferation and migration are important, and MOF can promote cell migration, thereby enhancing the wound healing effect. Specifically, the skin cells can be skin fibroblasts, but the present invention is not limited thereto. According to one embodiment of the present invention, when fibroblasts with scratches were treated with MOF, it was confirmed that with the passage of time and the increase in MOF concentration, the migration of fibroblasts was faster than the control, and it was confirmed that the composition comprising MOF had an excellent wound healing effect in promoting fibroblast migration (Experimental Examples 2 and Figure 2a and 2b ).
[0029] In one embodiment of the present invention, the concentration of MOF may be 0.001 to 10 μg / ml. Specifically, the concentration of MOF may be 0.001 μg / ml or more, 0.005 μg / ml or more, 0.01 μg / ml or more, 0.02 μg / ml or more, 0.03 μg / ml or more, 0.04 μg / ml or more, 0.05 μg / ml or more, 0.06 μg / ml or more, 0.07 μg / ml or more, 0.08 μg / ml or more, 0.09 μg / ml or more, 0.1 μg / ml or more, 0.11 μg / ml or more, 0.12 μg / ml or more, 0.13 μg / ml or more, 0.14 μg / ml or more 1μg / ml or more, 0.15μg / ml or more, 0.16μg / ml or more, 0.17μg / ml or more, 0.18μg / ml or more, 0.19μg / ml or more, 0.2μg / ml or more, 0.3μg / ml or more, 0.4μg / ml or more, 0.5μg / ml or more, 0.6μg / ml or more, 0.7μg / ml or more, 0.8μg / ml or more, 0.9μg / ml or more, 1μg / ml or more, 2μg / ml or more, 4μg / ml or more, 6μg / ml or more, 8μg / ml or more, or 10μg / ml or more , and the concentration of MOF can be 10 μg / ml or less, 8 μg / ml or less, 6 μg / ml or less, 4 μg / ml or less, 2 μg / ml or less, 1 μg / ml or less, 0.9 μg / ml or less, 0.8 μg / ml or less, 0.7 μg / ml or less, 0.6 μg / ml or less, 0.5 μg / ml or less, 0.4 μg / ml or less, 0.3 μg / ml or less, 0.2 μg / ml or less, 0.19 μg / ml or less, 0.18 μg / ml or less, 0.17 μg / ml or less, 0.16 μg / ml or less, 0 .15 μg / ml or less, 0.14 μg / ml or less, 0.13 μg / ml or less, 0.12 μg / ml or less, 0.11 μg / ml or less, 0.1 μg / ml or less, 0.09 μg / ml or less, 0.08 μg / ml or less, 0.07 μg / ml or less, 0.06 μg / ml or less, 0.05 μg / ml or less, 0.04 μg / ml or less, 0.03 μg / ml or less, 0.02 μg / ml or less, 0.01 μg / ml or less, 0.005 μg / ml or less, or 0.001 μg / ml or less. MOF can be used to ensure safety against cytotoxicity when treating injured parts of the skin and can be used for wound healing. The concentration of MOF is not limited as long as MOF is included as an active ingredient in the wound dressing to have safety, stability and wound healing ability.
[0030] In one embodiment of the present invention, the content of MOF may be 0.01 to 10 wt % based on the total weight of the composition. Specifically, based on the total weight of the composition, the content of MOF may be 0.01 wt % or more, 0.05 wt % or more, 0.1 wt % or more, 0.11 wt % or more, 0.12 wt % or more, 0.13 wt % or more, 0.14 wt % or more, 0.15 wt % or more, 0.16 wt % or more, 0.17 wt % or more, 0.18 wt % or more, 0.19 wt % or more, 0.2 wt % or more, 0.25 wt % or more, 0.3 wt % or more, 0.35 wt % or more, 0.4 wt % or more, 0.45 wt % or more. , 0.5 wt % or more, 0.55 wt % or more, 0.6 wt % or more, 0.65 wt % or more, 0.7 wt % or more, 0.71 wt % or more, 0.72 wt % or more, 0.73 wt % or more, 0.74 wt % or more, 0.75 wt % or more, 0.76 wt % or more, 0.77 wt % or more, 0.78 wt % or more, 0.79 wt % or more, 0.8 wt % or more, 0.85 wt % or more, 0.9 wt % or more, 0.95 wt % or more, 1 wt % or more, 5 wt % or more, or 10 wt % or more And based on the total weight of the composition, the content of MOF can be 10 wt % or less, 5 wt % or less, 1 wt % or less, 0.95 wt % or less, 0.9 wt % or less, 0.89 wt % or less, 0.88 wt % or less, 0.87 wt % or less, 0.86 wt % or less, 0.85 wt % or less, 0.84 wt % or less, 0.83 wt % or less, 0.82 wt % or less, 0.81 wt % or less, 0.8 wt % or less, 0.75 wt % or less, 0.7 wt % or less, 0.65 wt % or less, 0.6 %, 0.55 wt %, 0.5 wt %, 0.45 wt %, 0.4 wt %, 0.35 wt %, 0.3 wt %, 0.29 wt %, 0.28 wt %, 0.27 wt %, 0.26 wt %, 0.25 wt %, 0.24 wt %, 0.23 wt %, 0.22 wt %, 0.21 wt %, 0.2 wt %, 0.15 wt %, 0.1 wt %, 0.04 wt %, or 0.01 wt %. MOF can be used to ensure safety against cytotoxicity when treating injured parts of the skin and can be used for wound healing. The concentration of MOF is not limited as long as MOF is included as an active ingredient in a wound dressing to have safety, stability, and wound healing ability.
[0031] In one embodiment of the present invention, wounds include damaged body parts and refer to a state in which the body is damaged, also referred to as injuries. The wound may be selected from the group consisting of injuries, non-healing trauma, tissue destruction caused by radiation, abrasions, lacerations, avulsions, penetrating injuries, bullet wounds, cuts, burns, frostbite, sores, dry skin, keratosis, cracks, chapped skin, dermatitis, surgical or vascular disease wounds, bruises, corneal injuries, bedsores, abscesses, chronic ulcers, surgical suture sites, spinal injuries, gynecological wounds, chemical wounds, and acne, but the present invention is not limited thereto. In addition, in one embodiment of the present invention, wounds and injuries may be used interchangeably. According to one embodiment of the present invention, when the back area of a rat with a full-thickness skin wound was dressed with a dressing containing MOF according to one embodiment of the present invention, the wound healed over time, confirming that the composition containing MOF according to one embodiment of the present invention has wound healing ability and can therefore be used as a highly functional dressing for wound treatment or healing (Experimental Example 3 and Figure 3).
[0032] In one embodiment of the present invention, the composition may be a composition for external use on the skin, and may be a liquid, a cream, a paste, or a solid.
[0033] In one embodiment of the present invention, the composition may be a pharmaceutical composition or a cosmetic composition.
[0034] In one embodiment of the present invention, the pharmaceutical composition may be a composition for wound healing or treatment.
[0035] The pharmaceutical composition can be provided in all preparation forms suitable for topical application. For example, the pharmaceutical composition can be a skin external solution, suspension, emulsion, gel, patch or spray, but the present invention is not limited thereto. The preparation can be easily prepared by conventional methods known in the art, and surfactants, excipients, hydrating agents, emulsifiers, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizers, preservatives, preservatives or other commonly used adjuvants can be used.
[0036] In addition to the above ingredients, the pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient or diluent as needed. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not impair the effect of the present invention, and may include, for example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, a flavor or a preservative.
[0037] Representative examples of pharmaceutically acceptable carriers, excipients, or diluents can include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerol, gum arabic, alginate, calcium phosphate, calcium carbonate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable esters, Witepsol, Macrogol, Tween 61, cocoa butter, and laurinum.
[0038] In addition, in one embodiment of the present invention, when MOF is used as a quasi-pharmaceutical, one or more active ingredients having the same or similar functions may be additionally included. For example, MOF may include known wound healing components. The content of the additional components may be 0.0001 wt % to 10 wt % relative to the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety or ease of formulation of the MOF according to one embodiment of the present invention.
[0039] The active ingredient of the pharmaceutical composition according to one embodiment of the present invention can be changed according to age, sex, body weight, pathological condition and its severity, route of administration or the judgment of the prescriber. The dosage based on this factor is determined at the level of a person of ordinary skill in the art, and the daily dose can be, for example, 0.1 mg / kg / day to 5000 mg / kg / day, more specifically, 50 mg / kg / day to 500 mg / kg / day, but the present invention is not limited thereto.
[0040] In one embodiment of the present invention, the cosmetic material composition may be a composition for wound relief or recovery.
[0041] The cosmetic material composition can be provided in all preparations suitable for topical application. For example, the cosmetic material composition can be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam or an aerosol. The composition of such a preparation can be prepared according to conventional methods known in the art.
[0042] In addition to the above-mentioned materials, the cosmetic material composition may also contain other ingredients within the range that does not damage the main effect, specifically, it may contain ingredients that have a synergistic effect with the main effect. The cosmetic material composition according to one embodiment of the present invention may include materials selected from the group consisting of vitamins, polymer peptides, polymer polysaccharides and sphingolipids. In addition, the cosmetic material composition according to one embodiment of the present invention may include moisturizers, emollients, surfactants, ultraviolet absorbers, preservatives, bactericides, antioxidants, pH regulators, organic and inorganic pigments, fragrances, cooling agents or deodorants. Those of ordinary skill in the art can easily select the blending amount of the component within the range that does not damage the purpose and effect of the present invention, and the blending amount can be 0.01 to 5% by weight, specifically 0.01 to 3% by weight, based on the total weight of the composition.
[0043] In one embodiment of the present invention, the composition may be a quasi-drug composition. In addition, specifically, in one embodiment of the present invention, the composition may be a quasi-drug composition for wound healing comprising MOF as an active ingredient.
[0044] In addition to the above ingredients, the quasi-medical composition may further include a pharmaceutically acceptable carrier, excipient or diluent as required. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not impair the effect of the present invention, and may include, for example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, a flavor or a preservative.
[0045] Representative examples of pharmaceutically acceptable carriers, excipients, or diluents can include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerol, gum arabic, alginate, calcium phosphate, calcium carbonate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable esters, Witepsol, Macrogol, Tween 61, cocoa butter, and lauryl esters.
[0046] In addition, when the MOF according to an embodiment of the present invention is used as a medicine, it can additionally contain one or more active ingredients that exhibit the same or similar functions. For example, the MOF can include known wound healing components. The content of the additional components can be 0.0001 wt % to 10 wt % relative to the total weight of the composition, and the content range can be adjusted according to requirements such as skin safety or ease of preparation of the MOF according to an embodiment of the present invention.
[0047] The quasi-drug composition according to one embodiment of the present invention can be a disinfectant cleaner, a shower gel, an ointment, a wet wipe, a coating agent, etc., but the present invention is not limited thereto. The preparation method, dosage, method of use and components of the quasi-drug can be appropriately selected by conventional methods known in the art.
[0048] In another aspect, the present invention can provide a wound dressing comprising a hydrophilic superabsorbent polymer and MOF. The wound dressing can be used for wound healing. The description of MOF and wound is the same as above.
[0049] In one embodiment of the present invention, a hydrophilic super absorbent polymer refers to a polymer having hydrophilicity in a super absorbent polymer (SAP) having high absorption capacity. Super absorbent polymers can generally be obtained by crosslinking water-soluble polymers such as starch, polyacrylic acid, polyvinyl alcohol or polyethylene oxide to be insoluble in water, and can absorb hundreds of times more water in the molecule. The super absorbent polymer can specifically be polyacrylic acid, polyvinyl alcohol, gelatin, alginate or chitosan, but the present invention is not limited thereto. In addition, the hydrophilic super absorbent polymer can be one or more selected from the group consisting of hydrogel, hyaluronic acid, polyvinyl pyrrolidone, carboxymethyl cellulose, hydroxyethyl cellulose, xanthan gum and sodium hyaluronate, and specifically, a hydrogel. However, according to an embodiment of the present invention, the MOF can be dispersed, and when dressing the injured part of the skin, it not only ensures safety, but also shows the effect of wound healing. The type of hydrophilic super absorbent polymer is not limited, as long as it has safety, stability and wound healing ability to be included as an active ingredient of the wound dressing.
[0050] In one embodiment of the present invention, when the back area of a rat with a full-thickness skin wound was dressed with a wound dressing comprising a hydrogel in which MOF was dispersed according to one embodiment of the present invention, the wound healed over time, confirming that the wound dressing comprising a hydrophilic superabsorbent polymer containing MOF according to one embodiment of the present invention has an excellent injury or wound healing effect (Experimental Example 3 and Figure 3).
[0051] In another aspect, the present invention provides a method for wound healing, comprising administering or applying a composition comprising MOF to a subject in need of wound healing. In one embodiment of the present invention, the administration or application in the method can be performed by the administration or application method and the administration or application dosage disclosed in the specification.
[0052] In yet another aspect, the present invention provides use of MOF in preparing a pharmaceutical composition for wound healing.
[0053] In yet another aspect, the present invention provides use of MOF in preparing a cosmetic material composition for wound healing.
[0054] In another aspect, the present invention provides use of MOF in preparing a quasi-pharmaceutical composition for wound healing.
[0055] In yet another aspect, the present invention provides use of a composition comprising MOF in wound healing.
[0056] In yet another embodiment, the present invention provides a composition comprising MOF for use in wound healing.
[0057] In another aspect, the present invention provides a method for wound healing, comprising: applying a wound dressing comprising a hydrophilic superabsorbent polymer and MOF to a subject in need of wound healing. In one embodiment of the present invention, the application in the method can be carried out by the dressing method and dressing dosage disclosed in the specification.
[0058] In yet another aspect, the present invention provides use of a wound dressing comprising a hydrophilic superabsorbent polymer and MOF in the preparation of a wound dressing.
[0059] In yet another aspect, the present invention provides use of a wound dressing comprising a hydrophilic superabsorbent polymer and a MOF in wound healing.
[0060] In yet another aspect, the present invention provides a composition comprising a wound dressing for wound healing, the wound dressing comprising a hydrophilic superabsorbent polymer and a MOF.
[0061] Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to embodiments and experimental examples. However, the following embodiments and experimental examples are provided only for the purpose of illustration to help understand the present invention, and the scope of the present invention is not limited thereto.
[0062] [Example 1] Preparation of MOF-808 as MOF
[0063] To prepare MOF-808 as an active ingredient for wound healing compositions and wound dressings, the following process was performed.
[0064] Specifically, 0.485 g (1.5 mmol) of ZrOCl·8H2O as a metal part was dissolved in 11.25 mL of N,N'-dimethylformamide (DMF) in a 50 mL glass bottle, and 22.5 mL of formic acid was mixed. Here, 11.25 mL of a DMF solution in which 0.105 g (0.5 mmol) of trimesic acid was mixed was reacted at 130°C for 2 days. Then, the resulting product was washed with distilled water and acetone, transferred to distilled water and freeze-dried to prepare MOF-808.
[0065] [Example 2] Preparation of wound dressing
[0066] To prepare a wound dressing containing MOF-808 (as the MOF prepared in Example 1), the following process was performed.
[0067] Based on the total weight (500 ml), 0.1 to 10 wt % of a hydrogel (Sigma-Aldrich, poly (acrylic acid) 306223) as a hydrophilic superabsorbent polymer was dissolved in ultrapure water according to the desired viscosity. 0.1 wt % of MOF-808 prepared in Example 1 was added to the completely dissolved polymer solution and dispersed at 2,500 to 10,000 rpm for 1 hour using a homogenizer (CAT, X1740), and the resulting solution was transferred to a mechanical stirrer (Daihan Scientific, HT-120DX) and stirred at 500 to 1,000 rpm for 1 hour, while 0.1 wt % of triethanolamine (KPX) as a pH regulator was added dropwise to prepare a hydrogel containing MOF-808.
[0068] [Experimental Example 1] Confirmation of MOF cytotoxicity
[0069] In order to confirm the degree of toxicity of MOF-808 (as the MOF prepared in Example 1) to cells and its suitability as an active ingredient in a wound healing composition, the following experiment was performed. For this experiment, the method recommended in ISO 10993 Biological evaluation of medical devices - Part 5: In vitro cytotoxicity test, extract test was used, and the cell line used here was mouse fibroblasts (NIH 3T3, ATCC).
[0070] For cytotoxicity evaluation, mouse fibroblasts were used after 3 to 4 passages in DMEM (Gibco, DMEM, powder, high glucose) containing 10% fetal bovine serum (Gibco, Certified FBS). 5 Cells / well were seeded in a 96-well plate and cultured in DMEM by monolayer culture. The medium was removed and MOF-808 prepared in Example 1 was treated with 0.1, 1 or 10 μg / ml. Here, as a control, only DMEM was treated. After that, the fibroblasts of each sample were incubated in an incubator at 37°C and 5% CO2 for 24, 48 or 72 hours, observed under a microscope (OLYMPUS, CKX53 inverted microscope), and cell viability was determined by the MTT method. The results are shown in Figure 1 .
[0071] like Figure 1As shown, in experiments performed for 24, 48, and 72 hours, fibroblasts treated with 0.1 to 10 μg / ml MOF-808 showed cell viability corresponding to the control. Specifically, the cell viability values of 0.1 and 1 μg / ml for 24, 48, and 72 hours were similar to or better than the control. In addition, the cell viability values of 10 μg / ml for 48 and 72 hours were approximately 87.9% and 88.5% of the control. In particular, compared with the control, it can be seen that the cell viability of fibroblasts treated with MOF-808 below 0.1 μg / mL was extremely well maintained.
[0072] Therefore, it can be seen that the composition containing MOF according to one embodiment of the present invention has no significant difference in cytotoxicity compared to the control. Since this value corresponds to Level 1 (cell viability: 80% or more) of the cytotoxicity standard that meets the Korean Food and Drug Administration's wound healing material product approval standard (in the evaluation by the cytotoxicity test (elution method) described in ISO 10993-5, when more than 50% of the cells survive, and the cells are less hemolyzed and the gaps between the cells are not wide, Level 2 is applicable), the composition containing MOF according to one embodiment of the present invention has excellent safety when applied to the wound site.
[0073] [Experimental Example 2] Evaluation of MOF's wound healing ability (migration assay)
[0074] To evaluate the wound healing ability of MOF-808 (as the MOF prepared in Example 1), an in vitro scratch wound assay was performed as follows.
[0075] First, the same mouse fibroblasts as those used in Experimental Example 1 were cultured at 5 × 10 6 Cells / well were seeded in 6-well plates and cultured in DMEM (Gibco, DMEM, powder, high glucose) by monolayer culture. Scratches were made at 100% confluence, and then the suspended cells were removed. Subsequently, in order to confirm the efficacy of MOF-808 of Example 1, MOF-808 was dispersed in serum-free DMEM at 1, 10 and 100 ng / ml for treatment, and then the cells were observed under a microscope (OLYMPUS, CKX53 inverted microscope) at predetermined times (0, 5, 10 and 20 hours), and the area was calculated using Image J (NIH). The results are shown in Figure 2a and 2b Here, controls were treated with untreated serum-free DMEM.
[0076] like Figure 2a and 2bAs shown, in the experimental groups treated with 1, 10 and 100 ng / ml MOF-808, higher wound healing ability was shown compared with the control group. This result was due to the presence or absence of MOF-808, and as a result of measuring the migration of fibroblasts over time, it was confirmed that with the increase of time and MOF-808 concentration, that is, in the experimental group treated with 100 ng / ml MOF-808, the migration of fibroblasts was fast.
[0077] Therefore, the composition containing MOF according to one embodiment of the present invention has excellent wound healing ability, which is based on the wound healing ability of promoting fibroblast migration. Therefore, the composition containing MOF according to one embodiment of the present invention has excellent wound healing effect.
[0078] [Experimental Example 3] Evaluation of wound healing ability in an animal model treated with a wound dressing containing MOF
[0079] In order to evaluate the wound healing ability and confirm the efficacy of the wound dressing of the animal model of MOF-808 (as the MOF prepared in Example 1), the following animal test was performed using the wound dressing prepared in Example 2 (i.e., the wound dressing containing MOF-808). The animal test was performed using 4-week-old female (240 to 270 g) Sprague-Dawley rats as the animal model.
[0080] Specifically, in order to adapt to the laboratory environment, rats were raised in an environment with 20 to 2°C, 40 to 60% humidity, and automatic light and dark control at 12-hour intervals one week before the experiment. The dressings of the control group and the experimental group used in the animal experiment were sealed in aluminum bags and sterilized with gamma rays (25kGy) before dressing. The control was a hydrogel (0% MOF) that did not contain MOF-808 prepared in Example 1 as an active ingredient, and the experimental group was a hydrogel containing 0.2 weight% MOF-808 (0.2% MOF) based on the total weight of the hydrogel, that is, the hydrogel prepared in Example 2. In the animal experiment, a circular full-thickness wound with a diameter of 12 mm was made on the back skin of the rat, and the hydrogels of the control group and the experimental group were evenly applied to the wound site, respectively. The wound site was protected with a waterproof film Tegaderm (3M, Tegaderm 1626W), and then the film was replaced every 4 days. The results are shown in Figure 3a and 3b At this time, the wound healing process of rats without hydrogel or MOF-808 applied to the wound site was also observed at the same time interval, which corresponds to Figure 3a and 3b The comparison in .
[0081] from Figure 3a and 3bIt can be seen that after being treated with the wound dressing (hydrogel containing MOF-808) prepared in Example 2, the full-thickness wound on the back skin of the rats underwent epidermalization over time, leading to wound healing. Compared with the control group, it was confirmed that the wound recovery rate of the experimental group was high enough to be observed with the naked eye.
[0082] It can be seen from this that the MOF-containing composition and wound dressing according to one embodiment of the present invention have wound healing ability, and thus can be used as a highly functional dressing for wound healing.
[0083] Therefore, the MOF according to one embodiment of the present invention has excellent wound healing ability, and the wound dressing including the hydrophilic superabsorbent polymer in which the MOF is dispersed has excellent wound recovery ability and excellent wound healing ability.
Claims
1. Use of a metal organic framework material (MOF) in preparing a composition for wound healing, wherein: The metal organic framework material (MOF) is used as an active ingredient. The metal organic framework material is: MOF-808: Zr6O4(OH)4(BTC)2(HCOO)6.
2. The use according to claim 1, wherein: The MOF promotes the migration of skin cells.
3. The use according to claim 1, wherein: The content of the MOF in the composition is 0.001 μg / ml to 10 μg / ml.
4. The use according to claim 1, wherein: The MOF may be included in an amount of 0.01 wt % to 10 wt % based on the total weight of the composition.
5. The use according to claim 1, wherein: The wound is an injury.
6. The use according to claim 1, wherein: The wound is one or more selected from the group consisting of: a laceration, a sore, a surgical or vascular disease wound.
7. The use according to claim 1, wherein: The wound is one or more selected from the group consisting of: non-healing trauma, radiation-induced tissue destruction, abrasions, avulsions, penetrating wounds, bullet wounds, cuts, burns, frostbite, dry skin, keratosis, lacerations, skin cracks, dermatitis, contusions, corneal injuries, bedsores, abscesses, chronic ulcers, surgical suture sites, spinal injuries, gynecological wounds, chemical wounds and acne.
8. The use according to claim 1, wherein: The composition is a composition for external use on the skin.
9. The use according to claim 1, wherein: The composition is a pharmaceutical composition.
10. The use according to claim 1, wherein: The composition is a cosmetic material composition.
11. The use according to claim 1, wherein: The composition is a quasi-pharmaceutical composition.
12. The use according to claim 1, wherein: The composition is a wound dressing, which comprises a hydrophilic superabsorbent polymer and the metal organic framework material (MOF).
13. The use according to claim 12, wherein: The hydrophilic superabsorbent polymer is a hydrogel.
14. The use according to claim 12, wherein: The MOF may be present in an amount of 0.01 wt % to 10 wt % based on the total weight of the hydrophilic super absorbent polymer.
